- Home
- GENK vs SLGL Comparison
GENK vs SLGL Comparison
Compare GENK & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | SLGL |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 247.1M |
| IPO Year | 2023 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GENK | SLGL |
|---|---|---|
| Price | $1.62 | $72.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.67 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 31.0K | 10.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $8.46 | $122.71 |
| Revenue Next Year | $8.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.50 | $0.40 |
| 52 Week High | $6.50 | $97.97 |
Technical Indicators
Market Signals| Indicator | GENK | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 49.53 |
| Support Level | $1.66 | $71.01 |
| Resistance Level | $2.55 | $97.97 |
| Average True Range (ATR) | 0.14 | 11.29 |
| MACD | -0.01 | -1.59 |
| Stochastic Oscillator | 44.00 | 32.83 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.